{
    "clinical_study": {
        "@rank": "38611", 
        "arm_group": {
            "arm_group_label": "Suspicious skin lesions.", 
            "description": "No intervention is administered."
        }, 
        "brief_summary": {
            "textblock": "The use of MDS to access the presence of melanoma in the skin."
        }, 
        "brief_title": "Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Skin Lesions", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "A topical agent is applied to suspicious skin lesions and imaged. The images are analyzed to\n      provide a score that correlates with the probability for the presence of melanoma in the\n      lesion."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Individuals with skin lesion with one or more of the ABCDE features and recommended\n             for a skin biopsy.\n\n          -  The lesion is accessible to the imaging device, with at least 1 cm of skin around the\n             lesion that is accessible to the MDS.\n\n          -  Male and female \u2265 21 years old.\n\n          -  Subject is capable of giving written informed consent.\n\n          -  Primary excision.\n\n        Exclusion Criteria:\n\n          -  The lesion is less than 1 cm from the eyes.\n\n          -  The lesion is on the palms of hands or soles of the feet.\n\n          -  Mucosal lesion.\n\n          -  Pregnant females.\n\n          -  Low study procedure compliance.\n\n          -  Patients who are mentally or physically unable to comply with all aspects of the\n             study.\n\n          -  Undergoing chemotherapy.\n\n          -  Minor or legally incompetent and not able to sign the consent form.\n\n          -  Patient previously tested by MDS and was diagnosed with melanoma during the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Individual referred by a dermatologist or plastic surgeon for a skin biopsy or lesion\n        excision."
            }
        }, 
        "enrollment": {
            "#text": "660", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02056522", 
            "org_study_id": "OMS 001"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Melanoma", 
            "Skin Cancer"
        ], 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Haifa", 
                    "country": "Israel", 
                    "zip": "31096"
                }, 
                "name": "Rambam Health Care Campus"
            }, 
            "investigator": {
                "last_name": "Yehuda Ullmann, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_groups": "1", 
        "official_title": "Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging: the MDS (Melanoma Detecting System)", 
        "other_outcome": {
            "measure": "To further establish the safety of the MDS.", 
            "safety_issue": "Yes", 
            "time_frame": "28 days"
        }, 
        "overall_contact": {
            "email": "y_ullmann@rambam.health.gov.il", 
            "last_name": "Yehuda Ullmann, M.D.", 
            "phone": "+972-50-206-1666"
        }, 
        "overall_official": {
            "affiliation": "Rambam Health Care Campus", 
            "last_name": "Yehuda Ullmann, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To validate the performance of MDS", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02056522"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To calculate and specify the PPV and NPV of the MDS for melanoma detection when used as an adjacent tool to visual skin examination.", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "source": "Orlucent, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Orlucent, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}